FDA To Review Apotex Biosimilar Of Amgen Blockbuster Drug
Canada-based Apotex Inc. on Wednesday said the U.S. Food and Drug Administration is reviewing its proposed copycat of Amgen Inc.'s blockbuster biologic Neulasta, marking the agency's third known acceptance of a...To view the full article, register now.
Already a subscriber? Click here to view full article